Affordable Access

Access to the full text

Bleeding tendency and platelet function during treatment with romiplostim in children with severe immune thrombocytopenic purpura

Authors
  • Suntsova, Elena V.1
  • Demina, Irina M.1
  • Ignatova, Anastasia A.1
  • Ershov, Nikolay M.1
  • Trubina, Natalia M.1
  • Dobrynina, Juliya1
  • Serkova, Irina V.1
  • Supik, Zhanna S.1
  • Orekhova, Ekaterina V.1
  • Hachatryan, Lili A.1
  • Kotskaya, Natalia N.1
  • Pshonkin, Aleksey V.1
  • Maschan, Aleksey A.1
  • Novichkova, Galina A.1
  • Panteleev, Mikhail A.1, 2, 3, 4
  • 1 National Scientific and Practical Center of Pediatric Hematology, Oncology and Immunology, Moscow, 117198, Russia , Moscow (Russia)
  • 2 Center for Theoretical Problems of Physicochemical Pharmacology, Moscow, 119991, Russia , Moscow (Russia)
  • 3 Moscow State University, Faculty of Physics, Moscow, 119992, Russia , Moscow (Russia)
  • 4 Moscow Institute of Physics and Technology, Faculty of Biological and Medical Physics, Dolgoprudny, 141700, Russia , Dolgoprudny (Russia)
Type
Published Article
Journal
International Journal of Hematology
Publisher
Springer-Verlag
Publication Date
Mar 07, 2017
Volume
105
Issue
6
Pages
841–848
Identifiers
DOI: 10.1007/s12185-017-2207-3
Source
Springer Nature
Keywords
License
Yellow

Abstract

It has been suggested that platelet function in chronic immune thrombocytopenic purpura (ITP) may be abnormal. Thrombopoietin mimetics used for treatment can affect it, but the data remain limited. We investigated platelet function of 20 children diagnosed with severe ITP (aged 1–16 years, 12 females and eight males). Platelet functional activity in whole blood was characterized by flow cytometry before and after stimulation with SFLLRN plus collagen-related peptide. Levels of CD42b, PAC1, and CD62P, but not CD61 or annexin V, were significantly increased (P < 0.05) in resting platelets of patients before treatment compared with healthy donors. On average, PAC1 and CD62P in patients after activation were also significantly elevated, although some patients failed to activate integrins. Romiplostim (1–15 μg/kg/week s.c.) was prescribed to seven patients, with clinical improvement in six. Interestingly, one patient had clinical improvement without platelet count increase. Eltrombopag (25–75 mg/day p.o.) was given to four patients, with positive response in one. Others switched to romiplostim, with one stable positive response, one unstable positive response, and one non-responding. Platelet quality improved with romiplostim treatment, and their parameters approached the normal values. Our results suggest that platelets in children with severe ITP are pre-activated and abnormal, but improve with treatment.

Report this publication

Statistics

Seen <100 times